A letter from Prof. Philip James. Hon. Medical Advisor MS Therapy Centres The way the (Corona) virus acts in the body is now understood and the receptors on the surface […]
Coronavirus and High Dose Oxygen Therapy
Posts in the General category:
Virtual Summer Fete 2020
Swanley Therapy Centre’s annual Summer Fete fundraiser was originally planned for June 20th this year. Unfortunately due to the coronavirus outbreak affecting the whole country the event had to be […]
Effect of vitamin D supplements on MS activity
People with MS are often advised to take high doses of vitamin D, but there’s been very little research to assess what effect this might have.
Sign Up for Our Newsletter
Subscribe * indicates required Email Address * First Name Last Name Marketing Permissions Swanley Therapy Centre will use the information you provide on this form to be in touch with […]
The Evidence for Oxygen awarded the 2019 Nobel prize
We wanted to draw attention to an interesting article published in the HBOTT Dec 2019 Newsletter.
Bowen Therapy at Swanley Therapy Centre
Paul Dunn, an experienced Bowen Therapy practitioner, has started Bowen Therapy on Wednesday mornings. We will soon also have a second Bowen practitioner, Helen Malcolmson, starting on Thursday mornings.
Thank you to our supporters for 2020!
Thank you to all the companies who have supported us so far this year, either by their financial contributions or by donating prizes for our Summer Fete Fundraising Event.
Tysabri: reducing the risk of PML with extended interval dosing
Tysabri (natalizumab) is very effective for people with highly active relapsing remitting MS but it carries the risk of developing a rare but very serious brain infection called progressive multifocal […]
Sativex approved by NICE
Sativex, a cannabis based drug for MS related spasticity, has been approved by NICE as a cost effective treatment for the NHS in England.
Siponimod recommended for secondary progressive MS by EMA
The European Medicines Agency has recommended that a licence should be granted for Siponimod for the treatment of active secondary progressive MS.